Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia
AIDS, Volume 25, No. 17, Year 2011
Notification
URL copied to clipboard!
Description
OBJECTIVES:: This study's objective was to assess outcomes in HIV-1 and HIV-2 infected antiretroviral therapy (ART)-naïve patients starting ART in the Gambia, West Africa. DESIGN:: A cohort design was used to estimate survival in ART patients and determine whether survival and time to virologic failure varied across patient subgroups. METHODS:: Mortality, virologic failures and CD4 cell recovery were assessed in a clinical cohort of patients from the Genito-Urinary Medicine (GUM) clinic of the MRC Laboratories in the Gambia. Kaplan-Meier estimates of survival were determined for mortality and virologic failure. A Cox proportional hazards model was used to identify baseline demographic, clinical, immunologic and virologic factors associated with increased risk of death. RESULTS:: The overall Kaplan-Meier estimate of survival to 36 months was 73.4% (66.5, 80.3). Survival was marginally higher in HIV-2-infected patients compared to HIV-1-infected patients; it was significantly higher in patients with a baseline CD4 lymphocyte cell count of greater than 50 cells/μl compared to those with a baseline CD4 count of less than 50 cells/μl. CD4 cell recovery was faster in HIV-1-infected individuals compared to HIV-2-infected patients up to 24 months, although this did not result higher mortality in the latter group. No differences in virologic failure were observed by HIV type. CONCLUSION:: HIV-1 and HIV-2-infected patients receiving ART in a clinical setting in the Gambia had good survival to 36 months. HIV-2-infected patients did as well as HIV-1-infected patients in terms of long-term immunological and virological responses and overall survival. © 2011 Wolters Kluwer Health Lippincott Williams & Wilkins.
Authors & Co-Authors
Peterson, Ingrid
United States, New York
Columbia University
Togun, Oluwatoyin
Gambia
Medical Research Council uk the Gambia Unit
de Silva, Thushan I.
United States, New York
Columbia University
United Kingdom, London
Ucl Faculty of Medical Sciences
United Kingdom, Oxford
John Radcliffe Hospital
Oko, Francis
Gambia
Medical Research Council uk the Gambia Unit
Rowland-Jones, Sarah Louise
United Kingdom, Oxford
John Radcliffe Hospital
Jaye, Assan
Gambia
Medical Research Council uk the Gambia Unit
Senegal, Dakar
Université Cheikh Anta Diop de Dakar
Peterson, Kevin L.
Gambia
Medical Research Council uk the Gambia Unit
Belgium, Antwerpen
Prins Leopold Instituut Voor Tropische Geneeskunde
Statistics
Citations: 46
Authors: 7
Affiliations: 6
Identifiers
Doi:
10.1097/QAD.0b013e32834c4adb
e-ISSN:
14735571
Research Areas
Health System And Policy
Infectious Diseases
Study Design
Cohort Study
Study Locations
Multi-countries
Gambia